Form 8-K - Current report:
SEC Accession No. 0001104659-23-083433
Filing Date
2023-07-24
Accepted
2023-07-24 16:10:21
Documents
12
Period of Report
2023-07-19
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2321917d1_8k.htm   iXBRL 8-K 23010
  Complete submission text file 0001104659-23-083433.txt   195652

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA blph-20230719.xsd EX-101.SCH 3024
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE blph-20230719_lab.xml EX-101.LAB 34240
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE blph-20230719_pre.xml EX-101.PRE 22365
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2321917d1_8k_htm.xml XML 3326
Mailing Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059
Business Address 184 LIBERTY CORNER ROAD, SUITE 302 WARREN NJ 07059 908-574-4770
Bellerophon Therapeutics, Inc. (Filer) CIK: 0001600132 (see all company filings)

EIN.: 473116175 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36845 | Film No.: 231105147
SIC: 2834 Pharmaceutical Preparations